Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
BioNTech AG
BioNTech AG
Activities:
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Finance
BioNTech and Autolus announce strategic collaboration
The strategic collaboration will advance both companies' autologous CAR-T programmes towards commercialisation, pending regulatory authorisations
Manufacturing
AGC to support Pfizer-BioNTech Omicron vaccine
Plasmid DNA from AGC is already supplied as a starting material for the companies' COVID-19 vaccine
Ingredients
Pfizer and BioNTech announce early positive vaccine update
Collaboration has announced results from German Phase 1/2 COVID-19 vaccine study, including first T-Cell response data
Finance
BioNTech completes acquisition of Neon Therapeutics
Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases
Research & Development
BioNTech and Pfizer dose first cohort of Phase I/II COVID-19 vaccine trial
The trial is the first clinical trial of a COVID-19 vaccine candidate in Germany and there are plans to initiate trials in the US upon regulatory approval
Research & Development
Sanofi and BioNTech sign cancer immunotherapy partnership
BioNTech could receive more than US$300m in development, regulatory and commercial milestones
Research & Development
BioNTech and Siemens cooperate on production of personalised cancer vaccines
Siemens will develop and construct an automated and paperless manufacturing site
Subscribe now